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New benzopsoralen analogues were synthesized and their inhibitory effect on the growth of tumour-
tumour cell lines (MDA MB231 and TCC-SUP) was evaluated. The in vitro antitumour activity of the new
benzopsoralen analogues was discussed in terms of structureeactivity relationship. Molecular docking
studies with human-CYP2A6 enzymes were also carried out with the synthesized compounds to evaluate
the potential of these molecules to interact with the haem group of the enzymes. The results demon-
strated that the compounds that are able to interact with the iron ion of the haem cofactor and at the
same time with active site Asn297 are those that have better anti-proliferative activity.
© 2014 Published by Elsevier Masson SAS.1. Introduction
Psoralens are naturally occurring furocoumarins present in
many plant families such as Apicaceae and Umbelliferae [1]. Furo-
coumarins extracted from plants are commonly used as food ad-
ditives, in phytomedicine and as cosmetics [2]. Additionally,
Psoralen and 8-methoxypsoralen (8-MOP, named Xanthotoxin) are
used for the treatment of Psoriasis in combination with UVA irra-
diation (PUVA therapy) [3]. It is important to notice that these
compounds have also been reported to have an anti-cancer effect
independently of its photoactivation [4,5]. It has been reported that
Bergapten (5-methoxypsoralen) enhances p53 gene expression and
induces apoptosis in human breast cancer cells [6].
Psoralens have been developed as pharmaceuticals for a wide
range of disorders (vitiligo, psoriasis, skin cancers) that require cell
division inhibitors [7] and are known to interrupt drug metabolism
due to their ability to competitive and/or mechanistically inhibit a
variety of human cytochrome P450 enzymes, including CYP1A2,
CYP2A6 and CYP3A4/5 [8,9]. Xanthotoxin, Bergapten and Psoralen
have been reported to suicide-inactivate the human CYP2A6
(enzyme involved in the coumarin metabolism) [10,11] and theyEsteves).
.contribute to the programmed cancer cell death and increased
sensitivity to chemotherapy [10,11].
Some psoralens, e.g. Bergapten, have been demonstrated to
exert an anti-cancer effect against different cancers, independently
of its photoactivation [6]. For instance, Lee et al. [12] reported the
chemopreventive role of Bergapten in a human hepatocellular
carcinoma. The authors propose that there are at least three modes
of suppressive effects shown by Bergapten, namely killing the cells
directly; inducing apoptosis by arresting cells at the G2/M phase in
the cell cycle; and inducing apoptosis through an independent
pathway with cell cycle arrest at a given exposure time. It is also
pertinent to mention that structurally related Bergapten exerts its
anticarcinogenic properties by a cytotoxic effect, inducing
apoptosis and inhibiting cell proliferation. In the current work, no
mechanistic studies have been included, therefore only consider-
ations regarding cytotoxicity and a potential effect on cell prolif-
eration can be advanced.
The human CYP2A6 protein is involved in the metabolism of
coumarins [13] and is known to be overexpressed in several cancer
cells [14,15], including breast and bladder cancers. Therefore, it is an
adequate model for molecular docking studies of the compounds
herein synthesized. Previously, we reported that these compounds
interact very closely with the iron ion of the haem group of the
enzyme [4,5]. Ye and Zhang [16] demonstrated that the depletion of
iron (haem deﬁciency) caused the apoptosis of HeLa cells, which
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(involved in the programmed cell death). It appears that haem
deﬁciency inhibits cell growth by selectively interfering with the
progression of the S phase of the cell cycle. Indeed, the haem
altered metabolism has been associated with numerous diseases,
including cancer.
Earlier in our group Psoralen derivatives were synthesized and
their anti-proliferative effects on different human tumour cell lines
were demonstrated [4,5]. The molecular docking results of these
compounds with the CYP2A6 enzyme showed that, in general, the
compounds carrying few bulky groups attached to the coumarin
moiety adopted a conformation that allows the carbonyl group of
the coumarinmoiety to interact very closely with the iron ion of the
haem cluster. Interestingly, these compounds were found to have a
better ability to inhibit the proliferation of the three cell lines
studied (MDA MB231, HeLa, TCC-SUP).
In the current work, two angular benzopsoralen analogues
derived from 4-hydroxydibenzothiophene 1 were synthesized
(compounds 2 and 3, Scheme 1) and their biological activities were
evaluated. Other two linear benzopsoralen analogues derived from
2-hydroxydibenzofuran and 2-hydroxycarbazole (compounds 4
and 5, Scheme 2) were also synthesized and evaluated. One com-
pound devoid of a coumarin moiety, (E)-ethyl 3-(3-hydroxy-9H-
carbazol-9-yl)acrylate (10) (Scheme 3), was also obtained and
tested.2. Results and discussion
2.1. Chemistry
Benzopsoralen derivatives with sulphur nucleus were obtained
by Pechmann reaction using 4-hydroxydibenzothiophene 1 as the
precursor. Compound 1 was prepared by the reaction of dibenzo-
thiophene (commercial) with TMEDA, B(OBu)3 and n-BuLi in the
presence of 30% H2O2, in dry diethyl ether [17]. Although a good
resolution of the multiplicity of signals was not achieved, in the 1H
NMR spectrum it was possible to identify the signal corresponding
to the hydroxyl group at d 9.95 ppm and also the other seven ar-
omatic proton signals (d 7.02e8.28 ppm). By Pechmann reaction of
4-hydroxydibenzothiophene 1with ethyl acetoacetate and ethyl 2-
chloroacetoacetate in the presence of concentrated H2SO4 com-
pounds 2 and 3 were obtained in 21 and 53% yields, respectively
(Scheme 1). The NMR data for compound 2 are consistent with theScheme 1. Reagents and conditions: i) TMEDA, n-BuLi, rt/ reﬂux, 1 h, dry ether; ii) B(OB
chloroacetoacetate, conc. H2SO4, 8 h, rt.proposed structure, namely the presence of two doublets at 8.05
and 7.68 ppm, J ¼ 8.4 Hz belonging to protons H-5 and H-6,
respectively. The methyl group appears as a doublet at 2.56 ppm
due to the long range coupling with H-3 and therefore the signal of
H-3 is as an apparent doublet 6.37 ppm. For compound 3 1H NMR
spectrum showed the signals of protons H-5 and H-6 as doublets at
8.08 (J ¼ 8.4 Hz) and 7.69 ppm (J ¼ 8.7 Hz), respectively, a singlet at
2.70 for the methyl group and absence of H-3 signal, that conﬁrms
the formation of the product.
The benzopsoralen analogues 4 and 5were also prepared under
Pechmann conditions (Scheme 2). The compound 4 was obtained,
in 14% yield, from 2-hydroxydibenzofuran and ethyl 2-
chloroacetoacetate. Its formation was conﬁrmed by analysis of
the 1H NMR spectrum that showed the presence of singlets at 7.89
(H-11), 7.79 (H-5) and 2.70 (CH3) ppm. The reaction of 2-
hydroxycarbazole with ethyl 2-chloroacetoacetate afforded com-
pound 5 in 16% yield. By analysis of the 1H NMR spectrum the
presence of two singlets at 8.59 and 7.38 ppm for the protons H-5
and H-11, respectively, and a singlet at 2.67 (CH3) was observed.
Compound 6was prepared by reaction of cyclohexanonewith 4-
methoxyphenyl hydrazine according to the method described by
Rogers and Corson [18], in a yield of 71% (Scheme 3). 1H NMR
spectrum showed a singlet at d 7.56 corresponding to eNH and a
doublet at 6.93 ppm J ¼ 2.4 Hz corresponding to H-4 and the ex-
pected signals for the aliphatic protons. Dehydrogenation reaction
of compound 6 in p-cymene/water and in the presence of 10% Pd/C,
under reﬂux, afforded the carbazole 7 in 53% yield (Scheme 3). The
introduction of the eCHO group at 4-position of carbazole 7 was
attempted under the conditions of Vilsmeier-Haack formylation
(POCl3 in dry DMF) and a solid was obtained in 76% yield. However,
after analysis of the 1H NMR spectrum the absence of the signal
corresponding to the eNH and the presence of a singlet at
9.80 ppm, led to the conclusion that N-formylation had occurred
with formation of compound 8 (Scheme 3). Demethylation of 8
with a 1 M solution of BBr3 in CH2Cl2 under nitrogen atmosphere
gave compound 9, in 48% yield after puriﬁcation by column chro-
matography (Scheme 3). In the proton NMR spectrum the disap-
pearance of the OCH3 signal was observed together with the
presence of a singlet at d 9.60 ppm (OH group). The alkene 10 was
prepared by Wittig reaction between 9 and Ph3PCHCOOEt (in N,N-
diethylaniline, 15 h, reﬂux) (Scheme 3). The proton NMR spectrum
of the product showed two doublets at 8.54 (H-3) and 6.32 (H-2)u)3, 30% H2O2, reﬂux, 90 min; iii) ethyl acetoacetate, conc. H2SO4, 2 h, rt; iv) ethyl 2-
Scheme 2. Reagents and conditions: i) ethyl 2-chloroacetoacetate, 80% H2SO4, 4 days, rt; ii) ethyl 2-chloroacetoacetate, 80% H2SO4, 48 h, rt.
Scheme 3. Reagents and conditions: i) acetic acid, reﬂux, 4.5 h; ii) p-cymene, H2O, 10% Pd/C, reﬂux, 48 h; iii) dry DMF, dry CH2Cl2, POCl3, reﬂux, 3 h; iv) dry CH2Cl2, BBr3 in CH2Cl2,
N2 atmosphere, 24 h, rt; v) N,N0-diethylaniline, carbethoxymethylenetriphenylphosphorane, reﬂux, 15 h.
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formation of the product 10.2.2. Anti-proliferative effect on human cancer cell lines
The ability of the compounds 2e5 and 10 to inhibit the in vitro
growth of MDA MB231 and TCC-SUP cell lines was evaluated. TheTable 1
Anti-proliferative effect of the studied compounds on human cancer cell lines.
Compound Inhibition of cancer cell lines GI50 (mM)
MDA MB231 TCC-SUP
2 0.049 ± 0.002 0.253 ± 0.022
3 0.460 ± 0.038 0.311 ± 0.031
4 0.082 ± 0.003 0.243 ± 0.027
5 0.421 ± 0.031 0.149 ± 0.013
10 0.198 ± 0.017 0.025 ± 0.008results, given in concentrations that were able to cause 50% of cell
growth inhibition (GI50), are summarized in Table 1.
A high anti-proliferative activity was observed for all the com-
pounds even at the minimum concentration tested (0.5 mM).
Compound 2 was found to be the most active against MDA MB231,
while for TCC-SUP cells the compound 10 showed a higher anti-
proliferative effect. Furthermore, the compound 4 showed better
activity for the MDA MB231 cell line than compounds 3 and 5,
although for the TCC-SUP cell line it gave values on the same range
as the compounds 3 and 5. The results herein obtained are in
agreement with our previous studies using benzopsoralen ana-
logues [4,5].
As previously mentioned, it is expected that a compound that
interacts with the haem group of CYP2A6 will have an effect on the
cell proliferation and apoptosis, which can be the mechanism by
which psoralens exerted the observed anti-proliferative activity.
Some differences could be observed between the two different cell
lines (Table 1), namely in what regards the most active compound.
These differences could be due to distinct CYP2A6 expression
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different responsiveness to hormones (e.g. oestrogen) [19e22].2.3. Molecular docking
Given that psoralens have been shown to be potent inhibitors of
several enzymes from the cytochrome P450 superfamily, in the
current work molecular docking methodologies were used to pre-
dict the binding pose between each of these ligands and the
enzyme CYP2A6. The enzyme CYP2A6 was chosen since it is one of
the 57 CYP isoenzymes found in humans [23] and is involved in the
metabolism of several pharmaceuticals, carcinogens, and a number
of coumarin-type alkaloids [24,25].
The co-crystallized X-ray structure of Xanthotoxin in CYP2A6
(PDB code 1Z11) reveals that the substrate ﬁts very well in the
narrow binding site. The active site is formed by a cluster of
phenylalanine residues (Phe107, Phe111, Phe108, Phe209 and
Phe480) that line the “roof” of the active site and by the presence of
a single polar residue, Asn297 (Fig. 1). It is suggested that Asn297
inﬂuences substrate orientation, and metabolism, and therefore
might be critical for substrate recognition and binding. Indeed,
mutations of this residue often lead to dramatic changes in the
kinetics of the reaction that is catalysed by this enzyme.
The molecular docking results show that all the studied com-
pounds bind in the same region of the protein nearby the haem
cofactor (Fig. 1). Similarly to what was found in our previous mo-
lecular docking studies [4,5], the C]O group of compounds 2 and 5
binds very near to the iron ion of the haem cofactor (2.5 Å and
3.3 Å). The pyrrole and the thiophene rings point towards the
amino group of Asn297 (3.2 Å and 5.4 Å). Compounds 3 and 2 are
very similar; the only difference between them is the presence of aFig. 1. Molecular docking results for compounds 2e5 and 10. The substrates are represented
X-Ray structure containing the Xanthotoxin inhibitor has the PDB code 1Z11.chlorine atom bound to position 3 of the coumarin moiety. Inter-
estingly, the sulphur atom of thiophene ring of compound 3 no
longer interacts with the amino group of Asn297, neither the C]O
group interacts directly with the iron ion of the haem cofactor. The
methyl group and the chlorine atom interact now with the iron ion
(2.2 Å) and the thiophene ring is pointing towards the opposite
direction of Asn297. A similar trend is observed in compound 4. The
chlorine atom linked to position 3 of the coumarin moiety causes
the methyl group to be close to the iron ion of the cofactor (3.0 Å)
instead of the C]O group. In this case the benzofuran is still in close
contact with Asn297 (2.8 Å). This is possible only because the new
orientation of the molecule did not preclude this sort of interaction,
something that was not observed in compound 3. Product 10 has a
different scaffold from all the other compounds. However, the
bulky ester group attached to the carbazole ring interacts very
closely to the iron ion of the haem cofactor (2.5 Å). The hydroxyl
group that is attached to the carbazole moiety points towards
Asn297 (3.4 Å). This type of binding pose is in line with compounds
2 and 5.
Based on the measured anti-proliferative activity data and the
best scored solutions obtained from the molecular docking proto-
col, it can be concluded that the inhibitory activity of the com-
pounds is dependent on their ability to interact with the iron ion of
the cofactor and with Asn297. This result goes in line with our
previous results and is observed with compound 2 and 10 [4,5].
Compound 5 has a similar binding pose to these compounds but it
has poor anti-proliferative activity. The molecular docking results
suggest that this might be related with the poor interaction that
this compound has with Asn297 which causes the binding pose to
be less speciﬁc.in bonds, the haem, Asn297 and Cys439 in ball and stick, and the protein in cartoon. The
C.S. Francisco et al. / European Journal of Medicinal Chemistry 87 (2014) 298e305302Compound 4 also shows an interesting anti-proliferative activity
and similar to compounds 2 and 10. This compound forms a
hydrogen bond with Asn297 through the oxygen atom of the
benzofuran ring, and interacts with the iron ion of the haem
cofactor through the methyl group and the chlorine atom. This sort
of interaction is different to what is observed in compound 2 and 10
but based on the anti-proliferative activity data, endorses a similar
inhibitory effect. Compound 3 has a similar binding pose to com-
pound 4, but shows poor anti-proliferative activity. The molecular
docking results suggest that the reason behind this trend is related
with the lack of the interaction of this compound with Asn297 that
might induce a less speciﬁc binding pose.
3. Conclusions
Four new Benzopsoralen analogues were synthesized and their
biological activities were tested. All of them signiﬁcantly inhibited
the proliferation of two human tumour cell lines, which we pro-
posed to be mainly linked with the inhibition of CYP2A6.
The molecular docking results revealed that all the compounds
interact with the ferryl haem of CYP2A6 and this might be one of
the main causes that preclude the observed tumour cell prolifera-
tion. Comparing the anti-proliferative activity results of each
compound and the best scored solutions obtained from the mo-
lecular docking protocol, it may be concluded that the compounds
that are able to interact with the iron ion of the haem cofactor and
at the same time with the active site Asn297 are those that have
better anti-proliferative activity. Comparing our previous results
with those herein obtained, it becomes evident that the com-
pounds that do not interact with Asn297 have systematically lower
anti-proliferative activities. This may be related with the lack of
speciﬁcity in the binding pose of those compounds in the active site
of CYP2A6 that precludes an efﬁcient inhibitory activity.
4. Experimental
4.1. Chemistry
Melting points were determined on a Gallenkampmelting point
apparatus and are uncorrected. 1H NMR (300 MHz) and 13C NMR
(75.4 MHz) spectra were recorded on a Varian Unity Plus Spec-
trometer at 298 K or on a Bruker Avance III 400 spectrometer
(400 MHz for 1H and 100.6 MHz for 13C). Chemical shifts are re-
ported in ppm relative to solvent peak or TMS; coupling constants J
are given in Hz. Double resonance, HMQC (heteronuclear multiple
quantum coherence) and HMBC (heteronuclear multiple bond
correlation) experiments were carried out for complete assignment
of 1H and 13C signals in the NMR spectra. High-resolution mass
spectra (ESI-TOF) were obtained on a Bruker FTMS APEXIII spec-
trometer. Elemental analyses were performed on a Leco CHNS-932
instrument. TLC was carried out on plates coated with silica gel 60
F254. Column chromatography was performed on silica gel (70e230
or 230e400 mesh). Light petroleum refers to the fraction boiling in
the range 40e60 C.
4.1.1. Dibenzo[b,d]thiophen-4-ol (1)
To a solution of dibenzothiophene (2.50 g, 13.7 mmol) and
TMEDA (2.5 mL, 16.7 mmol) in dry diethyl ether (35 mL), under
stirring and nitrogen atmosphere, 2.5 M n-BuLi in hexane (5.9 mL,
14.8 mmol) was added dropwise at room temperature. The reaction
mixture was reﬂuxed for 1 h. Then it was cooled to 0 C and trib-
utylborate (4.0 mL, 14.8 mmol) was added, maintaining 0 C for
40 min and at room temperature for 1 h. After cooling to 0 C, 30%
H2O2 (5.0 mL) was added dropwise under vigorous stirring and the
mixture reﬂuxed for 90 min. After cooling, 5 M HCl (5.0 mL) wasadded and the layers were separated. The organic layer was washed
with a cold 10% solution of ammonium and iron(II) sulphate
(2  50 mL) and then extracted with 2 M NaOH solution
(2  100 mL), dried (MgSO4), ﬁltered and evaporated to dryness to
give a white solid which was identiﬁed as dibenzothiophene. The
aqueous phase was acidiﬁed with 5 M HCl until precipitation of a
beige solid which was separated by ﬁltration and dried and iden-
tiﬁed as the dibenzo[b,d]thiophen-4-ol (1). Yield: 0.860 g
(0.21 mmol, 31%). mp 146e147 C (Lit. mp 157e159 C) [26]. 1H
NMR (400 MHz, DMSO-d6): d 8.28 (d, 1H, J ¼ 9.2 Hz, H-9), 8.00 (d,
1H, J ¼ 8.8 Hz, H-1), 7.84 (d, 1H, J ¼ 8.0 Hz, H-6), 7.52 (m, 2H, H-7
and H-8), 7.38 (t, 1H, J ¼ 7.6 Hz, H-2), 7.03 (d, 1H, J ¼ 8.0 Hz, H-3)
ppm. 13C NMR (100.6MHz, DMSO-d6): d 153.06 (C-4), 140.38 (C-9a),
138.38 (C-5a and C-4a), 136.91 (C-9b), 127.64 (C-7 or C-8), 126.68
(C-2), 125.25 (C-7 or C-8), 123.78 (C-1), 122.81 (C-9), 114.01 (C-6),
112,13 (C-3) ppm.
4.1.2. 4-Methyl-2H-benzo[4,5]thieno[3,2-h]chromen-2-one (2)
A mixture of dibenzo[b,d]thiophen-4-ol 1 (0.200 g, 1.0 mmol),
ethyl acetoacetate (0.25 mL, 2.0 mmol) and chilled concentrated
H2SO4 (1.5 mL) was stirred at room temperature for 2 h. After
cooling the mixture was poured over crushed ice and the beige
solid formed was separated by ﬁltration and dried to give com-
pound 2. Yield: 0.055 g (0.21 mmol, 21%). mp 204e207 C. 1H NMR
(300 MHz, CDCl3): d 8.21 (dd, 1H, J ¼ 6.9 and 2.4 Hz, H-7), 8.05 (d,
1H, J ¼ 8.4 Hz, H-5), 7.95 (dd, 1H, J ¼ 6.6 and 2.4 Hz, H-10), 7.68 (d,
1H, J¼ 8.4 Hz, H-6), 7.57e7.52 (m, 2H, H-8 and H-9), 6.37 (app d,1H,
J ¼ 1.2 Hz, H-3), 2.56 (d, 3H, J ¼ 1.2 Hz, CH3) ppm. 13C NMR
(100.6 MHz, CDCl3): d 160.09 (C]O), 153.12 (C-4), 149.22 (C-6a),
140.91 (C-6b), 139.26 (C-11b), 134.83 (C-10a and C-11a), 127.91 (C-
8), 127.01 (C-4a), 124.90 (C-9), 123.26 (C-10), 122.32 (C-7), 120.81
(C-6), 117.22 (C-5), 114.41 (C-3), 19.19 (CH3) ppm. HRMS (ESI-TOF)
calcd for C16H10O2S 266.04015; found 267.04757 (MHþ).
4.1.3. 3-Chloro-4-methyl-2H-benzo[4,5]thieno[3,2-h]chromen-2-
one (3)
A solution of ethyl 2-chloroacetoacetate (0.28 mL, 2.0 mmol)
and dibenzo[b,d]thiophen-4-ol 1 (0.200 g, 1.0 mmol) was slowly
added to chilled concentrated H2SO4 (1.5 mL) and stirred at room
temperature for 8 h. The mixture was poured over crushed ice and
the beige solid formed was separated by ﬁltration and dried. Yield:
0.16 g (0.53 mmol, 53%). mp 239e245 C. 1H NMR (300 MHz,
CDCl3): d 8.21 (dd, 1H, J ¼ 6.6 and 2.4 Hz, H-7), 8.08 (d, 1H,
J ¼ 8.4 Hz, H-5), 7.96 (dd, 1H, J ¼ 6.6 and 1.8 Hz, H-10), 7.69 (d, 1H,
J ¼ 8.7 Hz, H-6), 7.60e7.51 (m, 2H, H-8 and H-9), 2.70 (s, 3H, CH3)
ppm. 13C NMR (100.6 MHz, DMSO-d6): d 155.02 (C]O), 148.80 (C-
4), 146.17 (C-11b), 139.35 (C-6a), 138.46 (C-4a), 134.12 (C-11a),
127.94 (C-8 or C-9), 125.04 (C-8 or C-9), 124.96 (C-10a), 123.04 (C-
10), 122.63 (C-7), 122.08 (C-6), 118.85 (C-3), 117.91 (C-5), 116.70 (C-
6b), 16.09 (CH3) ppm. HRMS (ESI-TOF) calcd for C16H9O2SCl
300.00118; found 301.00924 (MHþ).
4.1.4. 3-Chloro-4-methyl-2H-benzofuro[2,3-g]chromen-2-one (4)
To a mixture of 2-hydroxydibenzofuran (1.02 g, 5.43 mmol) and
ethyl 2-chloroacetoacetate (1.14 mL, 8.19 mmol), 80% H2SO4
(2.50 mL) was added and the mixture was stirred at room tem-
perature for 4 days. The mixture was poured onto ice, the precip-
itated brown solid was ﬁltered and recrystallized from hot ethanol,
affording a beige solid that was separated by ﬁltration and dried.
Yield: 0.217 g (0.16 mmol, 14%). mp 261e262 C. 1H NMR (300MHz,
CDCl3): d 8.02 (d, 1H, J ¼ 7.2 Hz, H-10), 7.89 (s, 1H, H-11), 7.79 (s, 1H,
H-5), 7.65e7.53 (m, 2H, H-7 and H-8), 7.42 (dt, 1H, J ¼ 1.8 and
6.9 Hz, H-9), 2.70 (s, 3H, CH3) ppm. 13C NMR (75.4 MHz, CDCl3):
d 157.88 (C]O and C-6a), 152.72 (C-5a), 147.58 (C-4 and C-11a),
129.34 (C-8), 127.73 (C-10b), 123.41 (C-9), 123.04 (C-10a), 121.73 (C-
C.S. Francisco et al. / European Journal of Medicinal Chemistry 87 (2014) 298e305 30310), 120.91 (C-3), 118.86 (C-4a), 112.03 (C-7), 108.25 (C-11), 106.56
(C-5), 16.66 (CH3) ppm. HRMS (ESI-TOF) calcd for C16H9ClO3
284.02402; found 285.0250 (MHþ).
4.1.5. 3-Chloro-4-methylpyrano[2,3-b]carbazole-2(10H)-one (5)
To a mixture of 2-hydroxycarbazole (1.0 g, 5.43 mmol) and ethyl
2-chloroacetoacetate (1.14 mL, 8.19 mmol), 80% H2SO4 (2.50 mL)
was added and the mixture was stirred at room temperature for
48 h. The mixture was poured onto ice, the brown precipitate was
separated by ﬁltration, washed with cold water and recrystallized
from EtOAc/light petroleum. The yellow solid formed was sepa-
rated by ﬁltration and dried. Yield: 0.254 g (0.90 mmol, 16%). mp
247e250 C. 1H NMR (300 MHz, DMSO-d6): d 11.66 (s, 1H, NH), 8.59
(s, 1H, H-5), 8.23 (d, 1H, J ¼ 7.8 Hz, H-6), 7.50 (dd, 1H, J ¼ 8.1 and
1.2 Hz, H-9), 7.43 (dt,1H, J¼ 1.2 e 7.7 Hz, H-8), 7.38 (s,1H, H-11), 7.23
(dt, 1H, J ¼ 1.2 and 7.5 Hz, H-7), 2.67 (s, 3H, CH3) ppm. 13C NMR
(75.4 MHz, DMSO-d6): d 156.66 (C]O), 150.00 (C-10a or C-11a),
149.81 (C-10a or C-11a), 141.81 (C-5a), 140.95 (C-9a), 122.08 (C-5b),
126.46 (C-8), 120.75 (C-4), 120.70 (C-6), 119.64 (C-7), 117.68 (C-5),
115.19 (C-3), 112.07 (C-4a), 111.26 (C-9), 97.10 (C-11), 16.48 (CH3)
ppm. HRMS (ESI-TOF) calcd for C16H10ClNO2 283.0400; found
283.0405.
4.1.6. 6-Methoxy-2,3,4,9-tetrahydro-1H-carbazole (6)
To a solution of cyclohexanone (0.30 mL, 2.86 mmol) in glacial
acetic acid (1 mL), methyl 4-methoxyphenyl hydrazine (0.501 g,
2.87 mmol) was added over 1 h. The mixture was reﬂuxed for 3.5 h
and left stirring until reaching room temperature. It was then
cooled in ice for 20 min and then 75% (v/v) aqueous MeOH (4 mL)
was added. The solid formedwas ﬁltered andwashedwith 12mL of
the same aqueous methanol to give a beige solid. Yield: 0.409 g
(2.03mmol, 71%). mp 93e95 C. 1H NMR (300MHz, CDCl3): d 7.56 (s
br, 1H, NH), 7.18 (d, 1H, J ¼ 9.0 Hz, H-1), 6.93 (d, 1H, J ¼ 2.4 Hz, H-4),
6.77 (dd, 1H, J ¼ 8.7 and 2.4 Hz, H-2), 3.86 (s, 3H, OCH3), 2.72e2.68
(m, 4H, H-6 and H-7),1.90e1.89 (m, 4H, H-5 and H-8) ppm. 13C NMR
(75.4 MHz, CDCl3): d 153.84 (C-3), 153.06 (C-8a), 130.68 (C-9a),
128.17 (C-4a), 110.90 (C-1), 110.50 (C-2), 110.02 (C-4b), 100.23 (C-4),
55.95 (OCH3), 23.33 (C-6 or C-7), 23.18 (C-5 and C-8), 20.94 (C-6 or
C-7) ppm. Anal. calcd for C13H15NO: C, 77.91; H, 7.223; N, 6.983%;
found: C, 77.58; H, 7.51; N, 6.96%.
4.1.7. 3-Methoxy-9H-carbazole (7)
To a solution of compound 6 (0.409 g, 2.03 mmol) in p-cymene
and H2O (5 mL, 4:1) 10% Pd/C (0.206 g) was added and the mixture
heated under reﬂux for 48 h. After cooling it was ﬁltered over Celite
and washed with boiling EtOAc. The ﬁltrate was evaporated to
dryness, and the product was obtained as an oil. Yield: 0.210 g
(1.07 mmol, 53%). 1H NMR (300 MHz, CDCl3): d 8.04 (d, 1H,
J ¼ 8.1 Hz, H-5), 7.57 (d, 1H, J ¼ 2.4 Hz, H-4), 7.41e7.40 (m, 2H, H-7
and H-8), 7.34 (d, 1H, J ¼ 8.7 Hz, H-1), 7.24e7.20 (m, 1H, H-6), 7.07
(dd,1H, J¼ 9.0 and 2.4 Hz, H-2), 3.94 (s, 3H, OCH3) ppm. NHwas not
observed.
4.1.8. 3-Methoxy-9H-carbazole-9-carbaldehyde (8)
To a solution of dry DMF (0.10 mL, 1.30 mmol) in dry CH2Cl2
(5 mL) cooled to 0 C, POCl3 (0.07 mL, 0.75 mmol) was slowly added
and the mixture was kept under stirring for 30 min. Then a solution
of compound 7 (0.100 g, 0.51 mmol) in dry CH2Cl2 (10 mL) was
added and the reaction mixture was heated under reﬂux for 3 h.
After cooling, water (10 mL) was added and the phases were
separated. The organic phase was sequentially washed with 10%
HCl (5 mL) and saturated NaHCO3 (2  5 mL), dried (MgSO4),
ﬁltered and evaporated to dryness. The product 8was obtained as a
solid, m.p. 67e70 C. Yield: 0.087 g (0.39 mmol, 76%). 1H NMR
(300 MHz, DMSO-d6): d 9.81 (s, 1H, CHO), 8.34 (d, 1H, J ¼ 8.4 Hz, H-1), 8.17 (d, 1H, J ¼ 8.4 Hz, H-5), 8.08 (d, 1H, J ¼ 7.2 Hz, H-8), 7.75 (d,
1H, J¼ 2.4 Hz, H-4), 7.51 (t,1H, J¼ 7.6 Hz, H-6), 7.42 (t,1H, J¼ 7.6 Hz,
H-7), 7.11 (dd, 1H, J ¼ 8.8 e 2.8 Hz, H-2), 3.87 (s, 3H, OCH3) ppm. 13C
NMR (100.6 MHz, DMSO-d6): d 159.31 (CHO), 156.70 (C-3), 138.15
(C-8a), 130.74 (C-9a), 127.24 (C-7), 125.07 (C-4b), 123.91 (C-6),
120.87 (C-5), 116.75 (C-1), 115.16 (C-2), 112.23 (C-4a), 111.41 (C-8),
104.07 (C-4), 55.64 (OCH3) ppm.
4.1.9. 3-Hydroxy-9H-carbazole-9-carbaldehyde (9)
To a cold solution of compound 8 (0.069 g, 0.31 mmol) in dry
CH2Cl2 (5 mL) under nitrogen atmosphere a 1 M solution of BBr3 in
CH2Cl2 (0.60 mL, 0.60 mmol) was slowly added. After reaching
room temperature the mixture was kept under stirring for 24 h and
then it was poured onto ice and extracted with CH2Cl2 (3  10 mL).
The organic phase was dried (MgSO4), ﬁltered and evaporated to
dryness. The residue obtained was puriﬁed by preparative layer
chromatography (eluent: diethyl ether/light petroleum, 1:1). The
compound 9 was obtained as a solid. Yield: 0.031 g (0.14 mmol,
48%). mp 149e150 C. 1H NMR (300 MHz, DMSO-d6): d 9.79 (s, 1H,
CHO), 9.60 (sl, 1H, OH), 8.25 (d, 1H, J ¼ 8.4 Hz, H-1), 8.06 (d, 2H,
J ¼ 8.4 Hz, H-5 and H-8), 7.49 (t, 1H, J ¼ 7.6 Hz, H-7), 7.46 (d, 1H,
J¼ 2.4 Hz, H-4), 7.39 (t, 1H, J¼ 7.6 Hz, H-6), 6.94 (dd, 1H, J¼ 8.8 and
2.0 Hz, H-2) ppm. 13C NMR (100.6 MHz, DMSO-d6): d 159.08 (CHO),
154.70 (C-3), 138.15 (C-8a), 129.84 (C-9a), 127.09 (C-7), 125.06 (C-
4b), 123.85 (C-6), 120.69 (C-5), 116.76 (C-1), 115.64 (C-2), 112.05 (C-
4a), 111.33 (C-8), 105.73 (C-4) ppm.
4.1.10. (E)-Ethyl 3-(3-hydroxy-9H-carbazol-9-yl)acrylate (10)
To a solution of compound 9 (0.070 g, 0.33 mmol) in N,N0-
diethylaniline (2.0 mL) carbethoxymethylenetriphenylphosphor-
ane (0.160 g, 0.46 mmol) was added and the mixture was reﬂuxed
for 15 h. After cooling, water was added (10 mL) and extracted with
CH2Cl2 (4  5 mL). The organic phase was washed with 5% HCl
(5  5 mL), dried (MgSO4), ﬁltered and evaporated to dryness. The
residue obtained was puriﬁed by preparative thin layer chroma-
tography (eluent: diethyl ether/light petroleum, 7:3) and a yellow
solid was obtained. Yield: 0.021 g (0.09 mmol, 28%). m.p. > 200 C
(dec.). 1H NMR (400 MHz, acetone-d6): d 8.54 (d, 1H, J ¼ 14.4 Hz, H-
3), 8.57 (s,1H, OH), 8.10 (dd,1H, J¼ 8.0 and 0.8 Hz, H-50or H-80), 7.90
(d, 1H, J ¼ 8.4 Hz, H-50or H-80), 7.81 (d, 1H, J ¼ 8.8 Hz, H-10), 7.61 (d,
1H, J ¼ 2.4 Hz, H-40), 7.58 (td, 1H, J ¼ 8.0 and 1.2 Hz, H-70), 7.39 (td,
1H, J ¼ 8.0 and 0.8 Hz, H-60), 7.15 (dd, 1H, J ¼ 2.4 and 8.8 Hz, H-20),
6.32 (d,1H, J¼ 14.0 Hz, H-2), 4.28 (q, 2H, J¼ 7.2 Hz, CH2), 1.35 (t, 3H,
J¼ 7.2 Hz, CH3) ppm. 13C NMR (100.6 MHz, acetone-d6): 168.18 (C]
O), 154.66 (C-30), 140.64 (C-80a), 137.65 (C-3), 133.61 (C-90a), 127.98
(C-70), 127.64 (C-40a), 126.14 (C-40b), 123.31 (C-60), 121.27 (C-50or C-
80), 116.49 (C-20), 113.97 (C-10), 112.50 (C-50 or C-80), 106.72 (C-40),
100.90 (C-2), 60.50 (CH2), 14.74 (CH3) ppm.
4.2. Tumour cell growth assay
The compoundswere evaluated for their anti-proliferative effect
on human cancer cell lines MDA MB231 (breast adenocarcinoma)
and TCC-SUP (bladder transitional cell carcinoma). The MDA
MB231 epithelial cell line was established from a pleural effusion
obtained from a 51-year-old female patient with breast cancer. The
TCC-SUP cell line was established from a tumour specimen resected
from the urinary bladder transitional cell carcinoma (undifferen-
tiated, grade IV) of a 67-year-old woman. All the cell lines were
kindly provided by IPATIMUP (Portugal). The cells were maintained
in an incubator with a 5% CO2 atmosphere and at 37 C. The culture
medium used was the Dulbecco's modiﬁed Eagle medium (DMEM)
(GIBCO®, Invitrogen, Barcelona, Spain) supplemented with Foetal
Bovine Serum (FBS) (GIBCO®, Invitrogen, Barcelona, Spain) (10% for
C.S. Francisco et al. / European Journal of Medicinal Chemistry 87 (2014) 298e305304MDA MB231 and 15% for TCC-SUP) and 1% of penicillin/strepto-
mycin (Invitrogen, Barcelona, Spain).4.2.1. Cell viability
Cells were exposed to ﬁve concentrations of compounds starting
from a maximum concentration of 75 mM. Compounds, prepared in
dimethyl sulfoxide (DMSO), were freshly diluted with cell culture
medium just prior the assays. Final concentrations of DMSO were
less than 1% not interfering with cell growth. The cell viability was
determined using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
method. A commercial kit was used according to the manufacturer
instructions (Promega, PROM G35800001, Lisbon, Portugal). In
these experiments,100 mL of cell suspensionwas added to eachwell
of a 96-well plate. Additionally, control wells were included con-
sisting of DMEMmedium and the compounds prepared in DMSO at
the concentrations under study. When a cell concentration of
1104 cells/mLwas obtained, adequate volumes of the compounds
solutions were added to the wells and incubated for 48 h. After-
wards, 20 mL of the CellTitter 96 Aqueous One Solution Cell Pro-
liferation Assay reagent (MTS) was added to each well and left in
the incubator (37 C, 5% CO2) for 2 h after which the cell viability
was quantiﬁed by recording the absorbance at 490 nm. For each
test compound and for each cell line a doseeresponse curve was
generated and the growth inhibition of 50% (GI50) of cell population
was determined (GI50 corresponds to the concentration of com-
pound that inhibits 50% of the cell growth). The results are
expressed as percentage of viable cells compared to the control and
represent an average of 3 independent cultures with 4 wells per
concentration in each experiment.4.3. Molecular docking
All the compounds were studied using the molecular docking
software AutoDock [27] and the vsLab plug-in Ref. [28]. The
structure of the receptor was built from the PDB structure 1Z10
containing the Human Microsomal P450 2A6. The ligands were
built with GaussView, protonated at physiological pH and opti-
mized with gaussian09 (HF/6-31G(d)). In the docking process the
Lamarckian genetic algorithm (LGA) was used. The number of
generations, energy evaluations, and docking runs were set to
370,000, 1,500,000, and 50, respectively. The types of atomic
charges were taken as Kollman-all-atom for the receptor and
Gasteiger for the compounds. The ﬁnal solutions were retrieved
from the molecular docking process according to the criteria of
interacting energy.Acknowledgements
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